Reversing the toxic effects of drugs of abuse
逆转滥用药物的毒性作用
基本信息
- 批准号:6912193
- 负责人:
- 金额:$ 9.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-01 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:GABA receptorP glycoproteinanalgesiaantidoteschemical structure functioncocainecrystallizationdrug abuse chemotherapydrug addiction antagonistdrug design /synthesis /productiondrug receptorsdrug tolerancegamma hydroxybutyrateinfrared spectrometrymass spectrometrynuclear magnetic resonance spectroscopyopiate alkaloidopioid receptoroverdosepharmacokineticstoxicology
项目摘要
DESCRIPTION (provided by applicant):
This proposal represents an application for a Research Career Award (K02) focused on the candidate's long-term goal of developing agents, which attenuate the toxic effects of drugs of abuse. The approach to achieving this goal is to have a research program that seeks to solve problems associated with drug abuse and dependence through testing hypotheses with chemistry-based approaches. The proposed research plan comprises of three projects, sharing the common theme of developing agents to attenuate the potentially lethal effects of drugs of abuse. In the case of opioids, the goal is to develop morphine-like analgesics which do not give rise to the severe constipation seen with current agents; for cocaine, the goal is to develop sigma receptor-based agents as potential treatments for cocaine overdose; for GHB, the goal is to develop a treatment for GHB overdose based on a mixed profile of GHB and GABA-B antagonism. My short-term approach to the latter two goals is to develop the current collaborations with Drs. France and Matsumoto to a point where I am able to take the lead as PI on new R01 submissions. My plans for the opioids is to develop a new research program based on pharmacokinetic mechanisms of tolerance, and initially submit an R21 application to gain valuable preliminary data. This approach is based on the hypothesis that as tolerance is reduced, the ever-increasing doses of morphine (which leads to the constipation) will not be required. My long-tern career goal is to develop these projects and my collaborations to the point where I am able to translate these medications into the clinic or emergency room. The candidate will spend 75% of his time on NIH-funded research. This award will allow the candidate to be relieved from many teaching and administrative responsibilities, thereby allowing him to focus on current and future research projects.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW COOP其他文献
ANDREW COOP的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW COOP', 18)}}的其他基金
Opiods with Delta Antagonist and Mu Agonist Activity
具有 Delta 拮抗剂和 Mu 激动剂活性的阿片类药物
- 批准号:
8101440 - 财政年份:2001
- 资助金额:
$ 9.74万 - 项目类别:
OPIOIDS WITH DELTA ANTAGONIST AND MU AGONIST ACTIVITY
具有 Delta 拮抗剂和 MU 激动剂活性的阿片类药物
- 批准号:
6845123 - 财政年份:2001
- 资助金额:
$ 9.74万 - 项目类别:
Opiods with Delta Antagonist and Mu Agonist Activity
具有 Delta 拮抗剂和 Mu 激动剂活性的阿片类药物
- 批准号:
8013890 - 财政年份:2001
- 资助金额:
$ 9.74万 - 项目类别:
OPIOIDS WITH DELTA ANTAGONIST AND MU AGONIST ACTIVITY
具有 Delta 拮抗剂和 MU 激动剂活性的阿片类药物
- 批准号:
6693440 - 财政年份:2001
- 资助金额:
$ 9.74万 - 项目类别:
Opiods with Delta Antagonist and Mu Agonist Activity
具有 Delta 拮抗剂和 Mu 激动剂活性的阿片类药物
- 批准号:
7758346 - 财政年份:2001
- 资助金额:
$ 9.74万 - 项目类别:
OPIOIDS WITH DELTA ANTAGONIST AND MU AGONIST ACTIVITY
具有 Delta 拮抗剂和 MU 激动剂活性的阿片类药物
- 批准号:
6628359 - 财政年份:2001
- 资助金额:
$ 9.74万 - 项目类别:
相似国自然基金
P-glycoprotein与Rack1和Src相互作用并促进耐药乳腺癌细胞侵袭转移的分子机制研究
- 批准号:81472474
- 批准年份:2014
- 资助金额:85.0 万元
- 项目类别:面上项目
相似海外基金
Inhibition or evasion of P-glycoprotein-mediated drug transport
抑制或逃避 P-糖蛋白介导的药物转运
- 批准号:
10568723 - 财政年份:2023
- 资助金额:
$ 9.74万 - 项目类别:
Physiological function of P-glycoprotein in sanctuary tissue barriers in teleosts
P-糖蛋白在硬骨鱼保护区组织屏障中的生理功能
- 批准号:
RGPIN-2020-04905 - 财政年份:2022
- 资助金额:
$ 9.74万 - 项目类别:
Discovery Grants Program - Individual
Studies of P-glycoprotein Drug Interactions - Administrative Supplement for Undergraduate Summer Research
P-糖蛋白药物相互作用的研究 - 本科生暑期研究行政补充
- 批准号:
10810072 - 财政年份:2022
- 资助金额:
$ 9.74万 - 项目类别:
Bacterial targeting of the P-glycoprotein/endocannabinoid axis for reducing intestinal inflammation in ulcerative colitis
细菌靶向 P-糖蛋白/内源性大麻素轴以减少溃疡性结肠炎的肠道炎症
- 批准号:
10537517 - 财政年份:2022
- 资助金额:
$ 9.74万 - 项目类别:
Drug, Nucleotide, and Lipid Interactions with P-glycoprotein
药物、核苷酸和脂质与 P-糖蛋白的相互作用
- 批准号:
10672242 - 财政年份:2022
- 资助金额:
$ 9.74万 - 项目类别:
Mechanisms of suicide attempts by loss of P-glycoprotein function in the blood-brain barrier
血脑屏障中 P-糖蛋白功能丧失导致自杀未遂的机制
- 批准号:
22K06774 - 财政年份:2022
- 资助金额:
$ 9.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Studies of P-glycoprotein Drug Interactions - Administrative Supplement for Equipment Purchase
P-糖蛋白药物相互作用研究-设备采购行政补充
- 批准号:
10795338 - 财政年份:2022
- 资助金额:
$ 9.74万 - 项目类别:
Physiological function of P-glycoprotein in sanctuary tissue barriers in teleosts
P-糖蛋白在硬骨鱼保护区组织屏障中的生理功能
- 批准号:
RGPIN-2020-04905 - 财政年份:2021
- 资助金额:
$ 9.74万 - 项目类别:
Discovery Grants Program - Individual